Kling Bio Validates its Proprietary B-Cell Technology for Rapid Response Against Emerging Viral Variants

Kling Bio California Massachusetts

Study demonstrated the use of immortalized B-cell libraries as a rapid and adaptable approach to therapeutic development against evolving viral threats Discovered 12 antibodies with potent neutralizing activity against multiple SARS-CoV-2 strains, including Delta and BA.5, through high-throughput B-cell screeningApplied ex vivo directed evolution to B-cell clones to enhance antibody neutralizing breadth and potency against emerging infectious disease variantsView original content:https://www.prnewswire.co.uk/news-releases/kling-bio-validates-its-proprietary-b-cell-technology-for-rapid-response-against-emerging-viral-variants-302549557.html